clinical trial · NCT07845487
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
Palisade Bio·phase2·recruiting·n = 204
Ulcerative Colitis (UC)Severe Ulcerative ColitisModerate Ulcerative ColitisPALI-2108PALI-2108Placebo
brief summary
The ASCENTRA-UC study is a phase 2 study testing PALI-2108 in patients with moderate to severe ulcerative colitis. Doses of drug will be compared against a placebo to see how well it works, how safe it is, and how the body responds to it.
started
Aug 28, 2026
primary completion
Oct 1, 2027
completion
Jun 1, 2028
last updated
Sep 29, 2026
official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Induction and Maintenance Therapy With PALI-2108 in Participants With Moderately to Severely Active Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol